Navigation Links
GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets,Phase II Study Endpoints of Immunogenicity and Safety Compared to,Licensed Vaccines

Investigational vaccine could offer protection for infants against Haemophilus influenzae type b and meningococcal disease

TORONTO, Canada, May 11, 2007 — GlaxoSmithKline (GSK) announced results from a Phase II vaccine clinical study presented this week at the Pediatric Academic Societies’ (PAS) Annual Meeting in Toronto, Canada. The new data suggest that the investigational Hib-MenCY-TT vaccine holds potential to protect infants in the first year of life against invasive disease caused by three strains of bacteria: Neisseria meningitidis serogroups C (MenC) and Y (MenY) and Haemophilus influenzae type b (Hib). The pediatric combination vaccine is currently in Phase III clinical studies and an application for licensure in the United States has not been submitted.

“Infants 12 months of age and younger are at the greatest risk of having meningococcal infections,” said Jacqueline M. Miller, M.D., Director, Clinical Research and Development and Medical Affairs, GlaxoSmithKline Biologicals. “This investigational Hib-MenCY-TT vaccine was designed to be administered at the 2-, 4-, 6-, and 12- or 15-month well child visits. If ultimately approved on this dosing schedule, it would not require the addition of shots to the current CDC-recommended pediatric immunization schedule.”

While the current CDC-recommended vaccination schedule calls for infants to be vaccinated against certain bacteria that cause meningitis such as Haemophilus influenzae type b and Streptococcus pneumoniae in the first year of life, there is currently no vaccine available to protect infants against any serogroup of Neisseria meningitidis.

About the Hib-MenC
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
2. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
3. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
4. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
5. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
6. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
7. Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
8. Intarcia Therapeutics Announces Presentation of Final Results From a Phase 2 Combination Study for the Treatment of Hepatitis C at the Digestive Disease Week Conference
9. Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure as Long-Term Monotherapy and in Combination Therapy
10. King Pharmaceuticals Reports Efficacy of Altace 20mg And Efficacy of a Combination of Altace 20mg And Hydrochlorothiazide 25mg For 24-hour Blood Pressure Control
11. King Pharmaceuticals Announces Plan to Present Results from Phase III Clinical Trial Evaluating ALTACE as Monotherapy and in Combination with Hydrochlorothiazide at the American Society of Hypertension Annual Meeting
Post Your Comments:
(Date:9/5/2008)...rom a Simple Blood Draw Have,the Potential to Serv...e of Indications,Usin... Currently Developing a Blood-Based ...JERSEY CITY, New Jersey, September 5,/PRNewswire-F... a leader in,the development of microRNA-based dia...
(Date:9/4/2008)...treatment of Acute Myeloid ...swire/ -- Celator Pharmaceuticals today,announced ... granted orphan,drug designation to CPX-351 (Cytar...atment of Acute Myeloid Leukemia (AML)., Celator ...hase 2,studies with CPX-351. The first Phase 2 stu...
(Date:9/4/2008)...R testing for the diagnostic ...ewswire/ -- The U.S. Food & Drug,Administration (F...Test,the first assay for quantitating Hepatitis B...e,s real-time PCR technology to quantify the amoun...octors may use viral load,testing results to estab...
(Date:9/4/2008)...ogists States UFE Meets Level,A Evidence for Clini...nal,Radiology Treatment Is Safe, Effective Option ...pt. 4 /PRNewswire-USNewswire/ -- The Society of,In... nearly 4,500 doctors,scientists and allied healt... through minimally invasive treatment intervention...
Breaking Medicine Technology:Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum 2Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum 3Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum 4Celator Pharmaceuticals Receives Orphan Drug Designation for Anticancer Agent CPX-351 2FDA Approves First Hepatitis B Viral Load Test 2FDA Approves First Hepatitis B Viral Load Test 3Society of Interventional Radiology Applauds Report's Uterine Fibroid Embolization Recommendations 2Society of Interventional Radiology Applauds Report's Uterine Fibroid Embolization Recommendations 3Beavers can help ease drought 2279 1Beavers can help ease drought 2279 2Music Therapy Improves Stroke Outcomes 12359 1Music Therapy Improves Stroke Outcomes 12359 2Grant to study if early BPA exposure leads to late prostate cancer 12355 1Grant to study if early BPA exposure leads to late prostate cancer 12355 2Standard test for blood sugar control not accurate in diabetic dialysis patients 12354 1Standard test for blood sugar control not accurate in diabetic dialysis patients 12354 2
...E)--Mar 12, 2007 - Ceragenix Pharmaceuticals,Inc.... on,infectious disease and dermatology, today anno...pound demonstrated virtually no biofilm,formation ...heters treated with Ceragenins,were soaked daily i...eated catheter. At day 21, the catheters were chal...
... March 12, 2007: Progen Industries Limited,(ASX: P...PI-88,Phase II liver cancer data has been accepted...an Association for the Study of the Liver,(EASL). ... liver,cancer trial at the American Association fo...In expectation of having final data fully analysed...
Other Medicine Technology:Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm,Formation in 21 Day Study 2Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm,Formation in 21 Day Study 3PI-88 Data to be Presented at Key International Conferences 2PI-88 Data to be Presented at Key International Conferences 3
(Date:9/4/2008)...ate Medicare Advantage (MA) plans will be paid an ...pared to what the same enrollee would have cost in... according to a new report from The Commonwealth F...andated by the Medicare Improvements for Patients ...ke effect beginning in 2010 had been fully in pla...
(Date:9/4/2008)... may be shortchanging their golden years by tappin...iversity of Illinois expert who has studied the fe..., More than three of every four Americans trim th...iming benefits early, a choice many might forego i... consequences, law professor Richard L. Kaplan say...
(Date:9/4/2008)...d pancreatic tumors , , THURSDAY, Sept. ...iscoveries involving genetic mutations of two dead...ncreatic cancer -- may lead to new treatments and ...represent the most complete genetic analysis to da...c map of these deadly cancers," Kenneth Kinzler, a...
(Date:9/4/2008)...ncology contract research organization, has publis...uanced Approach to Get Into the Clinic Faster.&quo...al research scientist with 35 years of experience,...mmonly viewed as straightforward investigations ru...rue integration with preclinical, regulatory and c...
Breaking Medicine News(10 mins):Health News:Extra payments to Medicare Advantage plans to total $8.5 billion in 2008 2Health News:New guide explores making the most of Social Security 2Health News:New guide explores making the most of Social Security 3Health News:Genetic Mutations Linked to Deadly Cancers 2Health News:Genetic Mutations Linked to Deadly Cancers 3Health News:Genetic Mutations Linked to Deadly Cancers 4Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 2Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 3
...during routine heel-prick or needle-stick blood te.../ Data from 1000 newborns in 11 studies was analy...st milk and breast-feeding was compared to a pacif...xperienced by infants when blood samples were take...
...care system to make doctors more accountable for t... Mary Harney said that the proposal includes vario...ommoners //on the Medical Council to 7 out of a to...e being introduced which would make it easy for th...
... man who suffered a burnt toe was ordered to under...of gangrene.// Derek Atkinson, 56, from Newton Ayc...a consultant at Bishop Auckland General Hospital. ...om a hot water bottle and since the symptoms seeme...
...sing exponentially in over-50s in Scotland causing...the rate// of sexually transmitted diseases had mo... Infections like chlamydia and herpes are also ri...tland. Health workers feel older citizens are ign...
Other Medicine News:Health News:Breast-fed Babies Experience Less Pain during Blood Tests 2
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),
The Guidant Fineline EZ leads with protective capsule are bipolar endocardial and designed for permanent implantation with pulse generators for cardiac pacing.
Medicine Products: